Literature DB >> 27570729

Contemporary Management of Vesicoureteral Reflux.

Derrick L Johnston1, Aslam H Qureshi2, Rhys W Irvine1, Dana W Giel1, David S Hains2.   

Abstract

The past 30 years have seen broad changes in the diagnosis and management of vesicoureteral reflux (VUR). Recently, a clinical debate has generated an open discussion in academic circles. New evidence has shifted treatment patterns away from widespread surgical management and recently brought into question some pharmacologic treatments. VUR is usually not hazardous by itself but is a significant risk factor for urinary tract infection (UTI) and less commonly, renal scarring and insufficiency. Given the costs and morbidity of UTI as well as the potential for significant renal injury, our approach remains conservative. Careful follow-up, parental education about pathophysiology and management of VUR and UTI, and management of bowel and bladder dysfunction (BBD) when present, are the foundation of treatment. Additionally, though we recognize the limitation of continuous antibiotic prophylaxis (CAP), we believe the benefits outweigh the risks and costs for many patients. Careful observation can be considered in patients with a single medical home, parental understanding of what UTI signs and symptoms are, low grade VUR, no history of complicated UTIs and close follow-up. Surgical management remains a relevant option for select patients who fail conservative measures with breakthrough UTIs or failure to resolve. Minimally invasive surgical options are available with acceptable outcomes though open ureteroneocystostomy still carries the highest success rate.

Entities:  

Keywords:  Behavioral modification; Bowel and bladder dysfunction; Continuous antibiotic prophylaxis; Surgery; Urinary tract infections; Vesicoureteral reflux

Year:  2016        PMID: 27570729      PMCID: PMC4996282          DOI: 10.1007/s40746-016-0045-9

Source DB:  PubMed          Journal:  Curr Treat Options Pediatr        ISSN: 2198-6088


  46 in total

1.  The evolution of vesicoureteral reflux management in the era of dextranomer/hyaluronic acid copolymer: a pediatric health information system database study.

Authors:  Thomas S Lendvay; Mathew Sorensen; Charles A Cowan; Byron D Joyner; Michael M Mitchell; Richard W Grady
Journal:  J Urol       Date:  2006-10       Impact factor: 7.450

2.  The mechanism of new onset contralateral reflux following unilateral ureteroneocystostomy.

Authors:  D A Diamond; R Rabinowitz; D Hoenig; A A Caldamone
Journal:  J Urol       Date:  1996-08       Impact factor: 7.450

3.  Vesicoureteral reflux in male and female neonates as detected by voiding ultrasonography.

Authors:  M Hiraoka; C Hori; H Tsukahara; K Kasuga; Y Ishihara; F Kotsuji; M Mayumi
Journal:  Kidney Int       Date:  1999-04       Impact factor: 10.612

4.  Effect of activated nitrofurans on DNA.

Authors:  Y Tu; D R McCalla
Journal:  Biochim Biophys Acta       Date:  1975-08-21

5.  The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children.

Authors:  W Farhat; D J Bägli; G Capolicchio; S O'Reilly; P A Merguerian; A Khoury; G A McLorie
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

6.  Management of non-neuropathic underactive bladder in children with voiding dysfunction by animated biofeedback: a randomized clinical trial.

Authors:  Sanam Ladi-Seyedian; Abdol-Mohammad Kajbafzadeh; Lida Sharifi-Rad; Babak Shadgan; Eileen Fan
Journal:  Urology       Date:  2014-11-11       Impact factor: 2.649

7.  The Swedish reflux trial in children: IV. Renal damage.

Authors:  Per Brandström; Tryggve Nevéus; Rune Sixt; Eira Stokland; Ulf Jodal; Sverker Hansson
Journal:  J Urol       Date:  2010-05-23       Impact factor: 7.450

8.  The role of dysfunctional voiding in failure or complication of ureteral reimplantation for primary reflux.

Authors:  H N Noe
Journal:  J Urol       Date:  1985-12       Impact factor: 7.450

9.  Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications.

Authors:  R Gleckman; N Blagg; D W Joubert
Journal:  Pharmacotherapy       Date:  1981 Jul-Aug       Impact factor: 4.705

10.  Randomized, double-blind, placebo-controlled trial of polyethylene glycol (MiraLAX®) for urinary urge symptoms.

Authors:  Nicol Corbin Bush; Anjana Shah; Theodore Barber; Mary Yang; Ira Bernstein; Warren Snodgrass
Journal:  J Pediatr Urol       Date:  2012-11-03       Impact factor: 1.830

View more
  5 in total

1.  Do Various Treatment Modalities of Vesicoureteral Reflux Have Any Adverse Effects in Pediatric Patients? A Meta-Analysis.

Authors:  Min Xie; Xiaogai Xu; Zhenjie Cao; Huijie Xiao
Journal:  Urol Int       Date:  2021-09-23       Impact factor: 2.089

2.  Evaluation of the Diagnostic Value of Contrast-Enhanced Voiding Urosonography with Regard to the Further Therapy Regime and Patient Outcome-A Single-Center Experience in an Interdisciplinary Uroradiological Setting.

Authors:  Constantin A Marschner; Vincent Schwarze; Regina Stredele; Matthias F Froelich; Johannes Rübenthaler; Thomas Geyer; Dirk-André Clevert
Journal:  Medicina (Kaunas)       Date:  2021-01-09       Impact factor: 2.430

Review 3.  Management of Vesicoureteral Reflux: What Have We Learned Over the Last 20 Years?

Authors:  Göran Läckgren; Christopher S Cooper; Tryggve Neveus; Andrew J Kirsch
Journal:  Front Pediatr       Date:  2021-03-31       Impact factor: 3.418

4.  Types of Parenchymal Changes Diagnosed on DMSA Scans of Kidneys Affected by Different Grades of Vesicoureteral Reflux.

Authors:  Adela Arapović; Ante Punda; Dubravka Brdar; Vesna Čapkun; Diana Bajo; Daniela Veljačić; Hrvoje Punda; Ana Simičić-Majce; Mirna Saraga-Babić; Katarina Vukojević; Marijan Saraga
Journal:  Med Sci Monit       Date:  2021-03-01

5.  Bilateral duplex collecting system with bilateral vesicoureteral reflux: a case report.

Authors:  Diataga Sylvestre Yonli; Marouene Chakroun; Selim Zaghbib; Delphine Ye; Abderrazak Bouzouita; Amine Derouiche; Mohamed Riadh Ben Slama; Haroun Ayed; Mohamed Cherif; Mohamed Chebil
Journal:  J Med Case Rep       Date:  2019-05-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.